Search

Selective fluorescence imaging of biomarkers in vivo and in situ for evaluating orthotopic hepatocellular carcinoma (HCC) chemotherapy remains a great challenge due to current imaging agents suffering from the potential interferences of other hydrolases. Herein, we observed that carbamate unit showed a high selectivity toward the HCC‐related biomarker carboxylesterase (CE) for evaluation of treatment. A near‐infrared two‐photon fluorescent probe was developed to not only specially image CE activity in vivo and in situ but also target orthotopic liver tumor after systemic administration. The in vivo signals of the probe correlate well with tumor apoptosis, making it possible to evaluate the status of treatment. The probe enables the imaging of CE activity in situ with a high‐resolution three‐dimensional view for the first time. This study may promote advances in optical imaging approaches for precise imaging‐guided diagnosis of HCC in situ and its evaluation of treatment. [ABSTRACT FROM AUTHOR]

Selective fluorescence imaging of biomarkers in vivo and in situ for evaluating orthotopic hepatocellular carcinoma (HCC) chemotherapy remains a great challenge due to current imaging agents suffering from the potential interferences of other hydrolases. Herein, we observed that carbamate unit showed a high selectivity toward the HCC‐related biomarker carboxylesterase (CE) for evaluation of treatment. A near‐infrared two‐photon fluorescent probe was developed to not only specially image CE activity in vivo and in situ but also target orthotopic liver tumor after systemic administration. The in vivo signals of the probe correlate well with tumor apoptosis, making it possible to evaluate the status of treatment. The probe enables the imaging of CE activity in situ with a high‐resolution three‐dimensional view for the first time. This study may promote advances in optical imaging approaches for precise imaging‐guided diagnosis of HCC in situ and its evaluation of treatment. [ABSTRACT FROM AUTHOR]

Noninvasive treatments for terminal cancer patients constitute a new trend in tumor treatment. Therefore, phototherapy, including photodynamic therapy (PDT) and photothermal therapy (PTT), has attracted considerable interest. Light and a photosensitizer (PS) are employed in both treatment methods. For PDT, the PS generates reactive oxygen species (ROS) when exposed to light, whereas for PTT, the PS generates heat. In this regard, the systematic design of new PSs has become an active area of phototherapy research in an effort to solve the problems associated with conventional PSs. In the past decade, activatable and heavy‐atom‐free PSs have become significant research areas. Therefore, we discuss our recent contributions to the PDT and PTT in this account. [ABSTRACT FROM AUTHOR]